Skip to content
AIPressRoom

FundingPhysical AI

Blue Arbor Secures $10.5M to Advance Prosthetic Control

Blue Arbor Technologies raised $10.5M Series A led by Ottobock to advance neuromuscular interfaces for prosthetic control.

By Raina Gimmel

Blue Arbor Technologies raises $10.5M

The big picture: Blue Arbor Technologies, a Michigan-based medical device company, has secured $10.5 million in Series A financing to further develop its neuromuscular interface systems for advanced prosthetic control. The round was led by strategic partner Ottobock, a global provider of prosthetics and bionics.

Why it matters:

  • Enhanced Control: Blue Arbor’s RESTORE Neuromuscular Interface System aims to enable more natural and independent control of robotic prosthetic limbs, allowing users to perform complex movements like individual finger control.
  • Strategic Partnership: The investment strengthens Blue Arbor’s collaboration with Ottobock, leveraging the latter’s expertise in manufacturing and commercializing prosthetic technologies to accelerate market readiness.
  • Regulatory Milestones: The company has achieved FDA Breakthrough Device Designation and acceptance into the FDA’s Total Product Life Cycle Advisory Program (TAP) Pilot, signaling regulatory support for its innovative approach.

How it works:

  • Direct Connection: The RESTORE System is designed to establish a direct link between a user’s peripheral nervous system and a robotic prosthetic limb, capturing detailed neuromuscular signals.
  • Dual Configuration: The platform is being developed in two versions: an External Sensing Unit (ESU) for initial clinical evaluation and an Internal Sensing Unit (ISU), a fully implantable next-generation interface.
  • Clinical Advancement: Funds will support feasibility studies and an Investigational Device Exemption (IDE) application to the FDA for U.S. clinical studies of the ESU, building on two successful human implantations.

The catch: While initial human implantations show promise, Blue Arbor has not disclosed detailed clinical performance data or a timeline for commercial availability. The market for advanced prosthetics is highly specialized, and translating pioneering research into scalable, widely adopted solutions will require navigating complex regulatory pathways and demonstrating significant functional improvements over existing technologies.

Key Facts

AIPressRoom Weekly

Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.

More in Physical AI

All